MedTrace Logo

Open-Label Surufatinib in European Patients With NET

NCT04579679 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-07-25

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).

Conditions

  • Neuroendocrine Tumours
  • Neuroendocrine Tumour of the Lung
  • Small Intestinal NET

Interventions

DRUG

Surufatinib

Surufatinib 300 mg oral once daily

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • William Schelman, MD, PhD · Hutchmed

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-13
Primary Completion
2024-09-06
Completion
2024-10-15
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Italy
  • Norway
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04579679 on ClinicalTrials.gov